Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P556 | DOI: 10.1530/endoabs.63.P556

1Endocrinology Hospital Hedi Chaker, Sfax, Tunisia; 2Hepatogastroenterology Hospital Hedi Chaker, Sfax, Tunisia; 3Radiology Hospital Hedi Chaker, Sfax, Tunisia.


Background: Fibroscan is a noninvasive medical dispositive for the evaluation of hepatic fibrosis based on the technique of pulse elastography. However, the interpretation of its value depends on several parameters.

Objective: The purpose of our work is to study the impact of diabetes on the value of liver fibroscan and to identify possible factors influencing this value in diabetics.

Materials and methodes: Our work is a cross-sectional comparative study with a prospective collection of data including diabetics and healthy controls between 1st August 2016 and 31 July 2018. Subjects with clinical, biological or radiological signs of liver disease were excluded. Among the controls, subjects with hepatic steatosis were excluded. A fibroscan, an hepatic ultrasound and a blood sampling (liver enzyme) were realised to our subjects. The measurement of the fibroscan value was performed by a single operator. We compared fibroscan values in diabetic patients against healthy controls.

Results: We recruited 91 healthy controls and 38 diabetics, 13 of whom were excluded due to the impossibility of performing fibroscan. The mean value of fibroscan was significantly higher in diabetics (4.9±1.25 Kpa VS 4.3±1 Kpa, P=0.045). The rate of steatosis in diabetics was 36%, the majority (55.5%) was with grade 1. The mean value of fibroscan was not influenced by the presence of steatosis (4.8±1.4 Kpa Vs 4.9±1.2 Kpa, P=0.9). Similarly, among diabetic patients, there was no correlation between fibroscan values and their age (P=0.14), sex (P=0.19) or BMI (P=0.06). The presence of overweight (P=0.2) or a recent change in weight (P=0.1), the presence of hypertension (P=0.9), kidney failure (P=0.5) or metabolic syndrome (P=0.9) did not influence the value of fibroscan in diabetics. However, the mean value of fibroscan was significantly higher in diabetic patients with dyslipidemia (P=0.09). There was no influence of diet, Hb A1c, or physical activity on the value of fibroscan in these patients. A negative correlation was found between the age of diabetes and the value of fibroscan liver (r=49%, P=0.012).

Conclusion: Our data shows that diabetes increases the value of liver fibroscan regardless of the presence of steatosis. In diabetics, fibroscan values increase with dyslipidemia and are negatively correlated with the age of diabetes.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.